[1] GoldsteinAL.From lab to bedside:emerging clinical applications of thymosin alpha-1[J].Expert OpinBiolTher,2009,9(5):593-608. [2] Naylor PH,Quadrini K,Garaci E,et al.Immunopharmacology of thymosin alpha 1 and cytokine synergy[J].Ann NY Acad Sci,2007,1112:235-244. [3] Romani L,Moretti S,Fallarino F,et al.Jack of all trades:thymosin α1 and its pleiotropy[J].Ann NY Acad Sci,2012,1269(1):1-6. [4] Schulof RS,Lloyd MJ,Cleary PA,et al.A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer[J].J Biol Response Mod,1985,4(2):147-158. [5] Maio M,Mackiewicz A,Testori A,et al.Large randomized study of thymosin alpha 1 interferon alfa or both in combination with dacarbazine in patients with metastatic melanoma[J].J Clin Oncol,2010,28:1780-1787. [6] Stefanini GF,Foschi FG,Castelli E,et al.Alpha-1 thymosin and transcatheter arterial chenoembolization in hepatocellular carinoma patients-a preliminary experience[J].Hepatogastroenterology,1998,45(19):209-215. [7] Cheng SQ,Wu MC,Chen H,et al.Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B[J].Zhonghua Zhong Liu Za Zhi,2005,27(2):114-116. [8] Acres B,Limacher JM.MUC1 as a target antigen for cancer immunotherapy[J].Expert Rev Vaccines,2005,4(4):493-502. [9] Nath S,Mukherjee P.MUC1:a multifaceted oncoprotein with a key role in cancerprogression[J].Trends Mol Med,2014,20(6):332-342. [10] Vassilaros S,Tsibanis A,Tsikkinis A,et al.Up to 15-year clinical follow-up of a pilot Phase Ⅲ immunotherapy study in stage Ⅱ breast cancer patients using oxidized mannan-MUC1[J].Immunotherapy,2013,5(11):1177-1182. [11] Quoix E,Ramlau R,Westeel V,et al.Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer:a controlled phase 2B trial[J].Lancet Oncol,2011,12(12):1125-1133. [12] Wurz GT,Kao CJ,Wolf M,et al.Tecemotide:Anantigen-specific cancer immunotherapy[J].Hum Vaccin Immunother,2014,10(11):3383-3393. [13] Hu B,Wang J,Guo Y,et al.Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine[J].Int Immunopharmacol,2016,33:108-118. [14] Wang F,Ni W,Liu G,et al.Escherichia coli maltose-binding protein (MBP) directly induces mouseTh1activation through upregulating TLR2 and downregulating TLR4expressions[J].Immunobiology,2015,220(6):782-788. [15] 台桂香,张凤吉,朱迅.重组人MUC1-MBP融合蛋白的抗肿瘤作用[J].中国肿瘤生物治疗杂志,2003,10(3):202-205. [16] Fang F,Ma J,Ni W,et al.MUC1 and maltosebinding protein recombinant fusion protein combined with Bacillus Calmette-Guerin induces MUC1-specific and nonspecific anti-tumor immunity in mice[J].Mol Med Rep,2014,10(2):1056-1064. [17] 赵小霞,马吉春,方芳,等.大肠杆菌麦芽糖结合蛋白(MBP)诱导小鼠Th1细胞的活化作用[J].中国免疫学杂志,2009,25(6):504-507. [18] Ni W,Wang F,Liu G,et al.TLR9 played a more important role than TLR2 in the combination ofmaltose-bindingprotein and BCG-induced Th1 activation[J].Mol Immunol,2016,79:32-37. [19] Li Q,Zhang H,Yu L,et al.Down-regulation of Notch signaling pathway reverses the Th1/Th2 imbalance in tuberculosis patients[J].Int Immunopharmacol,2018, 54:24-32. [20] Li L,Jing YB,Liu J,et al.Study on the correlation of the effect of entecavir on Th1/Th2 cytokines level in the treatment of chronic hepatitis[J].Zhonghua Gan Zang Bing Za Zhi,2017,25(8):606-611. [21] Kaminuma O,Saeki M,Nishimura T,et al.Differential contribution of adhesion molecules to Th1 and Th2 cell-mediated lung and bowel inflammation[J].Biol Pharm Bull,2017,40(10):1801-1805. |